The prevalence of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) in people with HIV is relatively common. Dr Richard Sterling (Virginia Commonwealth University, Richmond, VA, USA) joins touchINFECTIOUS DISEASES to discuss the pathogenesis and factors associated with the development of fatty liver in people with HIV, biomarkers proven effective for NAFLD in HIV, and the research priorities in HIV-associated NAFLD.
The presentation entitled: ‘Diagnosis and Epidemiology of NAFLD/NASH in HIV–Unique Opportunities and Challenges’ was presented at the American Conference for the Treatment of HIV (ACTHIV), May 5-7, 2022.
- Could you give us a brief overview of the prevalence of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) in people with HIV?
- What is known about the pathogenesis of NAFLD in HIV?
- What factors are associated with the development of fatty liver in people with HIV?
- What biomarkers have proven effective for NAFLD in HIV?
- What are the research priorities in HIV-associated NAFLD and what studies are ongoing?
Disclosures: Richard Sterling receives or has received grant/research Support from Abbie, Abbott, Gilead, and Roche.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Share this Video
Related Videos In HIV
Updated HIV primary care guidelines: Mamta Jain, ACTHIV 2023
Updated HIV primary care guidelines provide evidence-based and standardized approaches to manage individuals living with HIV, addressing their unique needs and challenges. By following these guidelines, healthcare providers can enhance patient outcomes and stay abreast of the latest research and treatment advancements in HIV care. In this interview, we speak with Dr Mamta Jain (UT […]
Managing liver complications and drug-drug interactions in HBV-HIV co-infection: ACTHIV 2023 with Jessie Torgersen
Liver complications and drug-drug interactions in HBV viremia in HIV patients are common, so it is important to consider complications and follow appropriate guidelines for patients when prescribing treatment. In this interview, we speak with Dr Jessie Torgersen (University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA) to explore considerations for healthcare professionals, including liver complications […]
HIV-HBV co-infection screening and monitoring guidelines: ACTHIV 2023, Jessie Torgersen
Screening and managing HIV-hepatitis B virus (HBV) co-infection is important due to increased risks in patients, therefore it is important to ensure standard practices involve comprehensive assessment, including serological testing and liver function evaluation, and healthcare professionals follow guidelines for regular monitoring to assess disease progression and treatment response. In this interview, we speak with […]